With a weatherproof IP54 rating and new TruToneâ„¢ technology, PARAGON redefines color fidelity and control for more refined creative expression in indoor and outdoor environments
LAS VEGAS, Dec. 4, 2024 /PRNewswire/ -- Elation, a global leader in advanced entertainment lighting solutions, is excited to unveil the PARAGON Series at LDI 2024 in Las Vegas, marking the first time the U.S. industry can experience this revolutionary technology up close. Designed as "the new standard" for professional lighting, the PARAGON Series delivers powerful, precision lighting that combines state-of-the-art innovation and robust weatherproof rating with an authentic understanding of designers' creative aspirations.
Visitors to Booth #2224 will be transported to a retro-futuristic spaceport lounge, a gateway to lighting's next frontier, where Elation's latest innovations, including the PARAGON series, will be on full display. This immersive booth balances cutting-edge technology with mid-century aesthetics, setting the stage for a journey through lighting's next era.
Combining multiple fixture roles in a single, adaptable design, PARAGON offers unmatched flexibility without compromise and has already generated anticipation across the lighting community. LDI attendees will be the first to see it in action and have the opportunity to place orders for this groundbreaking series, which blends striking design, superior light quality, and variable color fidelity control in a lightweight and compact package.
"The PARAGON Series is our highest state-of-the-art fixture yet and represents our dedication to pushing creative boundaries," said Matthias Hinrichs, Product Manager at Elation. "It combines our most advanced lighting technology, offering lighting designers unprecedented control and creative options, while also meeting the needs of production companies. PARAGON offers unprecedented color control and can adapt to any application from arena shows to outdoor events."
Engineered to withstand the rigors of demanding professional environments, PARAGON's IP54 weatherproof rating offers protection against water and dust ingress, meaning it performs reliably in any indoor space and temporary outdoor environment, elevating its versatility for multi-event use. PARAGON delivers consistent performance no matter the circumstances yet requires little maintenance.
Key Features of the PARAGON Series:
With immersive product demonstrations, and an otherworldly light show every hour, Elation's "Experience Tomorrow" booth is where professionals can get familiar with PARAGON and learn how it's designed to elevate their lighting projects to unprecedented heights.
Schedule an On-Site Interview: To arrange an interview or demo during the show, please contact pr@zenmedia.com.
For additional information please visit: https://www.futureoflighting.co
About Elation
At Elation, we represent the elite in the lighting industry. We design and manufacture a comprehensive range of best-in-class entertainment lighting products valued by production/rental houses and lighting designers worldwide. Our dedication to extraordinary quality and creative solutions has established us as the go-to choice for professionals. With a storied legacy of brilliance, our influence extends from iconic stages to cutting-edge studios across the globe. We also offer an advanced line of lighting control products through Obsidian Control Systems and a full range of dependable specialty effects called Magmatic. We invite you to take a closer look at www.elationlighting.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
First Look at Elation's PARAGON Series at LDI 2024: A New Benchmark in Versatile, Precision Lighting for Entertainment
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- The Chinese University of Hong Kong's Faculty of Medicine (CU Medicine) has, for the first time, discovered novel microbial signatures associated with inflammation of the gastrointestinal (GI) tract and transformed such signatures into clinically applicable non-invasive tests for early diagnosis and timely intervention. This invention can effectively differentiate common chronic gut disorders and is expected to minimise the need for endoscopies. Utilising nearly 6,000 faecal samples from different regions and ethnicities, the researchers have developed the world's first ddPCR test targeting selected unique bacterial species. This novel non-invasive diagnostic test is a reliable tool to differentiate irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), and is expected to be ready for clinical use in 2027. The findings were published in Nature Medicine.
Lack of a reliable, accurate, non-invasive test for IBD diagnosis
IBD, a growing GI disease in Asia, often shares similar symptoms such as recurrent abdominal pain and diarrhoea with IBS, a common functional GI disorder. Delayed IBD treatment can lead to chronic inflammation of and ulcers in the digestive tract. Severe cases may require the removal of a damaged intestine or the creation of a stoma.
Professor Francis KL Chan, Choh-Ming Li Professor of Medicine and Therapeutics at CU Medicine, Director of the Centre for Gut Microbiota Research and Co-Director of Microbiota I-Center (MagIC), said: "Globally, over eight million people experience GI symptoms yearly and likely need endoscopies. Colonoscopy and histology with CT or MRI scans are commonly used for IBD diagnosis but there is not yet a reliable blood or stool test. Surging demand for colonoscopies may result in long waiting times and delayed treatment. There is an urgent need for a non-invasive, accurate diagnostic test for IBD."
Discovery of microbiome biomarkers for IBD diagnosis
CU Medicine researchers performed metagenomic sequencing of 5,979 faecal samples with or without IBD – ulcerative colitis or Crohn's disease – from 11 countries, featuring different ethnicities. They identified microbiota alterations in IBD and uncovered 10 unique bacteria species associated with UC and nine associated with Crohn's disease.
Postdoctoral Fellow Dr Zheng Jiaying from the Department of Medicine and Therapeutics, said: "We found that IBD patients had more toxin-producing bacterial genes in the gut, such as Adherent-invasive E. coli and Proteus mirabilis, and they lacked a variety of bacterial species with anti-inflammatory functions."
Assistant Professor Wendy Zhang Jingwan from the same department, added: "We constructed machine learning diagnostic models for IBD based on the novel bacterial markers and found that the models performed well in diagnosing ulcerative colitis and Crohn's disease with an area under the curve of over 0.94."
Transforming bacterial markers into a rapid, effective, clinically applicable innovation for IBD diagnosis
To transform findings into clinical applications, researchers developed multiplex ddPCR technology to facilitate rapid, effective IBD diagnosis. Validation in independent cohorts and a public dataset showed a sensitivity and specificity of nearly 90% for IBD diagnosis. The innovation has received the Silver medal in Geneva International Exhibition of Inventions 2024.
Professor Siew Ng, Croucher Professor in Medical Sciences and Director of MagIC, said: "The incidence of IBD is rising rapidly in Asia, and it is expected that the number of patients in China will exceed 1.5 million by 2025. CU Medicine has been a pioneer in the research of IBD diagnosis, treatment and prevention. We have now developed a first-in-class, microbiome-based, next-generation diagnostic tool for chronic intestinal diseases. We are also conducting large scale transethnic, multicentre studies to further explore the potential of these biomarkers in disease monitoring, drug response prediction and patient stratification in IBD."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms
